Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.90 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.90 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876851 | 1.00 | EGFR (0.90) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL14671695 | 1.00 | EGFR (0.90) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL15876897 | 0.94 | EGFR (1.00) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL15876896 | 0.94 | EGFR (1.00) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL15876895 | 0.94 | EGFR (1.00) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL14671648 | 0.92 | EGFR (0.76) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL15877091 | 0.88 | EGFR (1.00) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL15877090 | 0.88 | EGFR (1.00) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL15876899 | 0.87 | EGFR (1.00) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL15876902 | 0.87 | EGFR (1.00) | EGFRERBB2ABL1PDGFRBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | claimed |
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2014-07-24 | — | — | US | claimed |
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2014-07-24 | — | — | US | disclosed |
| WO-2013013640-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | 上海医药集团股份有限公司 (CN) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | WEE1, WEE2, CYP4F11 | EGFR 4406/4885ERBB2 4001/4885ABL1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.